Genetic Characterization of Movement Disorders and Dementias

Genetic Characterization of Movement Disorders and Dementias

Quick Info:

Status:
Currently Recruiting
Estimated Enrollment:
12000
Phase:
Treatment Type:
Sample Collection
Trial Type:
Observational
Sponsor:
National Institute on Aging (NIA)
Primary Investigator:
Contact Information:

Trial Goal:

Tests to Expect:

Update Notes:

4/11/2019No significant updates
1/30/2019No significant updates
1/5/2019No significant updates
12/22/2018No significant updates
12/8/2018No significant updates
10/26/2018No significant updates
8/8/2018No significant updates
5/4/2018No significant updates
4/25/2018No significant updates
4/11/2018No significant updates
4/4/2018No significant updates
3/23/2018No significant updates
1/5/2018No significant updates
9/29/2017No significant updates
7/11/2017No significant updates
4/25/2017No significant updates
4/20/2017No significant updates
1/24/2017No significant changes
1/11/2017No significant updates
11/10/2016No significant updates
10/26/2016No significant updates
8/31/2016Description updated
11/17/2015Recruitment status/Enrollment criteria updated.
10/20/2015Protocol updated.
8/19/2015No significant updates.
6/1/2015Trial has been suspended.
5/13/2015Enrollment criteria updated.
6/25/2014No significant updates.
3/18/2014No significant updates.
2/19/2014No significant updates.
1/7/2014Description updated.
12/31/2013No significant updates.
12/19/2013New clinical trial added

Locations:

National Institute of Aging Clinical Research Unit, Baltimore, 21224

Other Information:

Purpose: This study aims to further characterize the genetic basis of movement disorders, including ALS.
Eligibility: Both genders, healthy volunteers accepted, 2 years or older.
Details: The objective of this study is to ascertain individuals with a clinical diagnosis of a movement disorder or dementia, their affected and unaffected family members, and unrelated, healthy individuals (to provide control samples); to characterize their phenotypes; and to identify and further characterize genetic contributions to etiology by collecting blood samples, saliva samples, and/or skin biopsies on these individuals for DNA and induced Pluripotent stem (iPs) cell line preparation.
Collaborator(s):
  • National Institutes of Health Clinical Center (CC) ( National Institute on The first aim of this protocol is to collect families with a history of movement disorder in an attempt to clone the causative gene. The second aim of this protocol isAging (NIA) )
News Articles and Summaries:
ALS Forum:
First Published on Clinicaltrials.gov: 12/12/2013
ClinicalTrials.gov ID: NCT02014246
Trial Protocol as Published on Clinicaltrials.gov:
ClinicalTrials.gov